Oramed Pharmaceuticals
ORMP
19 hedge funds and large institutions have $11.1M invested in Oramed Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 8 reducing their positions, and 5 closing their positions.
14% less funds holding
Funds holding: 22 → 19 (-3)
19% less capital invested
Capital invested by funds: $13.7M → $11.1M (-$2.6M)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
74% less call options, than puts
Call options by funds: $70K | Put options by funds: $269K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAM
Tocqueville Asset Management
New York
|
+$88.9K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$13.7K |
| 3 |
Citigroup
New York
|
+$8.89K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$3.28K |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$2.67K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
-$229K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$164K |
| 3 |
D.E. Shaw & Co
New York
|
-$44.8K |
| 4 |
Morgan Stanley
New York
|
-$37K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$29K |
ORMP Hedge Fund Activity: Q3 2014 in Review
19 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2014, worth a combined $11.1M — down 19% from $13.7M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of ORMP and 2 opened new positions — a net loss of 3 holders — while 8 trimmed existing stakes and 3 added.
The largest buyer was Tocqueville Asset Management, adding an estimated $88.9K. The largest seller was Stifel Financial, cutting an estimated $229K.
- 19 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2014, down from 22 in Q2 2014.
- Funds reported $11.1M of Oramed Pharmaceuticals stock for Q3 2014, down 19% quarter-over-quarter.
- 2 funds opened new Oramed Pharmaceuticals positions in Q3 2014 and 5 closed out, a net change of -3 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2014 was Tocqueville Asset Management, an estimated $88.9K added.
- The largest Oramed Pharmaceuticals seller in Q3 2014 was Stifel Financial, an estimated $229K sold.
Based on aggregated 13F filings for Q3 2014.